BioPharm International, February 2013

Features

Viral Vaccine Manufacturing

Tony Hitchcock of Cobra Biologics discusses challenges posed by production of viral vectors for vaccines.

The Vaccine Scene

By Jose Castillo, PhD

A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.

Automated Concentration and Diafiltration of Multiple siRNA Samples

By Rebecca Arvary , Deborah R. Cohen , Steven Vaughan , Catherine Blake

Project: transfer a manual concentration/diafiltration process for siRNA production.

Assessing Development Needs for Biobetters and Biosimilars

By Christina Satterwhite, PhD

Development requirements and regulatory guidance for biosimilars and biobetters.

Therapeutic Antibodies in Review

By K. John Morrow, Jr., PhD , Rathin C. Das, PhD

Innovative products and a range of indications drive the therapeutic antibody market.

Navigating Emerging Markets: Eastern Europe

By Jill E. Sackman, PhD

Eastern Europe is moving towards a goal of harmonized regulations.

Guest Editorial

Offering a Biopharma View of Social Media

By Aaron Davidson

Ever since Twitter launched in 2006 and Facebook became mainstream, most industries have sought ways to connect with their consumers through social media.

Global Reports

Report from India

By Jane Wan

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.

Regulatory Beat

GMP Compliance Becomes Prominent Enforcement Issue

By Jill Wechsler

Shortages spur efforts to overhaul manufacturing oversight.

Perspectives on Outsourcing

End of the Dedicated CMO?

By Jim Miller

Is the contract-only CMO an endangered species?

Boot Camp Business Guide

Facility Design and Operation: A Primer

NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.

Manufacturing Best Practices

Relevance Regained

By Simon Chalk

Improvement strategy should be linked to business strategy.